SeaStar Medical’s Lead Product Candidate, The Selective Cytopheretic Device, Included In Consensus Statement For Pediatric Acute Kidney Injury In First Pediatric Acute Disease Quality Initiative Meeting
– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI
– The Company expects the FDA to